weekly-digest

Why Cancer Drugs Fail—And When Surgery Isn’t Needed

Dan Manning

Dan Manning

— 17 min read
Share

This week’s research is defined by two powerful tensions: the drive to understand why treatments fail, and the growing case for doing less. On the molecular front, scientists finally cracked open one of oncology’s most frustrating puzzles — why BET inhibitors, which looked extraordinary in the lab, have repeatedly flopped in clinical trials. The answer involves a fundamental misunderstanding of what BRD2 and BRD4 actually do, and it points directly toward more selective drug design. That theme of resistance — and routes around it — ran through nearly every cancer type this week, from AML stem cells swapping enzymes to evade PI3K blockade, to TNBC cells rewiring their metabolism through SIRT5 to survive chemotherapy.

On the clinical side, the week’s most consequential finding may be the active surveillance data for DCIS. A randomized trial found that women who chose watch-and-wait for early-stage ductal carcinoma in situ had similar survival outcomes to those who underwent immediate surgery — a result that could reshape how tens of thousands of women make treatment decisions each year. Add to that new questions about surveillance colonoscopy in elderly patients and expert calls to integrate obesity medicine into routine cancer care, and a clear theme emerges: precision in when to intervene, not just how. Prevention is also making noise this week, with large-scale confirmation that the HPV vaccine cuts cancer risk in males and a sobering study linking household radon to a 30% higher ovarian cancer risk.

other-cancer

This category delivered some of the week’s most mechanistically interesting findings. Two stories stood out: the long-awaited explanation for BET inhibitor clinical failures — BRD2 and BRD4 have fundamentally opposite roles, meaning pan-BET drugs have been working against themselves — and zeaxanthin’s surprise appearance as an immune enhancer that boosts T cell strength and amplifies checkpoint immunotherapy. The lung CT incidental findings study adds immediate clinical relevance: screening programs ordered for lung cancer may be doing double duty, catching signals for entirely separate cancers in the same high-risk population.

breast-cancer

Breast cancer research this week split between practice-changing clinical findings and deep molecular work on resistance. The DCIS active surveillance trial is the headline — similar survival to immediate surgery, with obvious implications for how patients weigh treatment options going forward. On the molecular side, SIRT5 emerges as a metabolic resistance driver in triple-negative breast cancer, while a striking new study on tunneling nanotubes reveals that cancer may actively spread its precancerous state to healthy neighboring cells through physical connections — reframing early carcinogenesis as a communicable process rather than isolated mutation events.

lung-cancer

Lung cancer generated a rich mix of clinical and molecular insights this week. The incidental findings CT study has immediate practical relevance — lung screening programs may be doing double duty, flagging signals for extrapulmonary cancers in the same high-risk cohort. On the molecular side, the identification of POU2F1 as the master transcriptional regulator of DLL3 gives clinicians a potential upstream predictor for who will respond to tarlatamab and related SCLC therapies. The BRCA1/2 paradox in lung cancer — worse overall survival but better immunotherapy response — also demands clinical attention as precision oncology decisions grow more complex.

colorectal-cancer

Colorectal cancer generated compelling findings across prevention, screening, and treatment this week. The most striking basic science result: a massive 9,000-patient study found that only colorectal cancer — uniquely among all cancer types — harbors a consistent microbial fingerprint in its tumor tissue, pointing to the gut microbiome as a specific carcinogenic driver rather than a general bystander. On the clinical side, new questions about surveillance colonoscopy in elderly patients with prior adenomas add important nuance to blanket guidelines, while a next-generation fluoropyrimidine and an oral immune-boosting pill offer tangible near-term treatment advances.

blood-cancer

Blood cancer research this week combined sobering epidemiology with encouraging mechanistic breakthroughs. The therapy-related leukemia data is a cautionary note: oncology’s success at treating primary cancers is generating a growing wave of treatment-induced AML, which has nearly tripled in incidence over 30 years. On the more hopeful side, the AML PI3K resistance study is a textbook example of modern resistance science — when leukemic stem cells escape PI3K blockade by activating EZH1, researchers found they could close that escape route with a rational combination strategy. The myelofibrosis work adds a new humanized model and a credible drug target (SPP1) to a disease that has long suffered from both.

Other Research

This week’s broader research landscape covered remarkable ground — from glioblastoma’s microenvironmental vulnerabilities to a genuinely surprising discovery that CA19-9, the standard pancreatic cancer blood test, actively promotes liver metastasis rather than merely tracking disease. The finding that common cold virus antibodies cross-react with liver cancer cells points to an accidental form of natural immune protection that could inform therapeutic vaccine design. In brain tumors, combining CDK9 inhibitors with FDA-approved antidepressants showed synergistic killing of diffuse midline glioma — a childhood cancer with almost no effective treatments and a setting where brain-penetrant, already-approved drugs have obvious appeal.

Project Ideas This Week

This week’s project ideas span the full spectrum — from high-feasibility advocacy toolkits grounded in landmark clinical findings to medium-complexity research infrastructure the field is clearly missing. Several ideas flow directly from this week’s biggest stories: the DCIS active surveillance trial, the colorectal microbiome fingerprint, the therapy-related leukemia surge, and the CA19-9 metastasis revelation. Here are 26 ideas worth considering.

Colorectal Cancer Microbiome Discovery Platform

Analysis of 9,000+ patients revealed that only colorectal cancer — not other cancer types — consistently harbors distinct microbial communities, suggesting the gut microbiome has a unique relationship with colorectal carcinogenesis that could be exploited for diagnostics and treatment.

Feasibility: Medium

GBM Tumor Microenvironment Drug Target Atlas

Non-cancerous brain support cells were found to promote glioblastoma growth through paracrine signaling, and blocking this communication dramatically slowed tumor growth — revealing that GBM’s microenvironment contains targetable vulnerabilities that are being systematically overlooked by drug…

Feasibility: Medium

BET Inhibitor Target Selectivity Database

BRD2 and BRD4 have fundamentally distinct functions — BRD2 prepares genes for activation while BRD4 triggers transcription — meaning that pan-BET inhibitors have been disrupting gene regulation in counterproductive ways, and the field now needs selective BRD4 inhibitors.

Feasibility: Medium

Cancer Nutrition-Immunity Research Tracker

Zeaxanthin — a carotenoid supplement already taken for eye health — strengthens T cells and enhances immunotherapy effectiveness in preclinical models, suggesting that common dietary compounds may meaningfully modulate cancer immune responses and warrant systematic investigation.

Feasibility: Medium

DCIS Decision Navigator

A randomized trial shows active surveillance for DCIS produces similar ipsilateral invasive breast cancer survival as immediate surgery — a landmark result that means thousands of women per year could potentially avoid surgery, but only if they can access clear information to make an informed…

Feasibility: Medium

Lung Screening Incidental Findings Follow-Up Tracker

Significant incidental findings on lung screening CT are associated with a substantially increased risk of extrapulmonary cancer diagnosis in the following year — meaning lung screening programs are detecting signals for multiple cancer types, but follow-up infrastructure for incidental findings is…

Feasibility: Medium

Prostate Cancer MRI Prognostic Integrator

Pre-treatment MRI features provide independent prognostic information beyond PSA, Gleason grade, and clinical stage in prostate cancer — yet most existing risk calculators don’t integrate MRI findings, creating a gap between what imaging tells us and how treatment decisions are made.

Feasibility: Medium

Processed Meat Cancer Warning Label Advocacy Toolkit

The Physicians Committee for Responsible Medicine has petitioned the USDA to add colon cancer warning labels to processed meats — a science-backed public health intervention supported by WHO Group 1 carcinogen designation that lacks a centralized advocacy coordination resource.

Feasibility: High

PostMast: Post-Mastectomy Pain Syndrome Tracker and Community

Post-mastectomy pain syndrome (PMPS) affects a significant subset of mastectomy patients with severe, prolonged neuropathic pain — yet it remains under-recognized, under-treated, and under-studied, partly because patients lack tools to track their symptoms and communicate their experience to…

Feasibility: Medium

Therapy-Related Leukemia Risk Calculator for Cancer Survivors

Therapy-related AML has tripled over 30 years as more cancer survivors live longer after genotoxic chemotherapy and radiation — yet patients and oncologists rarely have accessible tools to quantify this long-term risk when making treatment decisions or planning survivorship surveillance.

Feasibility: Medium

Obesity-Oncology Integrated Care Finder

GLP-1 receptor agonists and bariatric surgery are now proven effective obesity treatments with potential direct anti-cancer effects, but oncology practices and obesity medicine remain siloed — creating a coordination gap for the large fraction of cancer survivors with obesity.

Feasibility: Medium

Colonoscopy Decision Aid for Older Adults

Elderly patients with prior adenomas face very low absolute colorectal cancer risk relative to competing mortality risks — yet surveillance colonoscopy is still widely recommended as routine, even in patients where the procedure’s risks and burdens may outweigh realistic cancer prevention benefits.

Feasibility: Medium

Home Radon Cancer Risk Calculator for Women

High residential radon was linked to a 30% higher ovarian cancer risk in postmenopausal women — extending radon’s known cancer risk beyond lung cancer and providing new evidence that home radon testing has broader cancer prevention relevance for women.

Feasibility: High

HPV Vaccination Equity Tracker for Males

Large-scale evidence now confirms the 9-valent HPV vaccine cuts cancer risk in males — yet male HPV vaccination rates lag significantly behind female rates in most countries, creating a preventable cancer burden that could be visualized and addressed through data-driven advocacy.

Feasibility: High

CA19-9 Beyond the Biomarker: Patient Education Hub

CA19-9 — the blood test every pancreatic cancer patient gets — is not just a passive indicator of disease; it actively promotes liver metastasis by helping tumor cells stick to liver blood vessels via E-selectin. This mechanistic insight has immediate implications for how patients and clinicians…

Feasibility: High

Lung Cancer Organoid Model Registry

Patient-derived organoids that faithfully recapitulate keratinizing squamous cell carcinoma histology — including spontaneous keratin pearl formation — fill a critical gap in LUSC preclinical modeling, but these rare models are scattered across individual labs with no shared registry.

Feasibility: High

GBM Spatial Heterogeneity Drug Sensitivity Portal

Neurosphere cultures from different regions of the same GBM tumor show completely different drug sensitivities, yet standard drug screening uses single-biopsy cell lines — meaning published drug sensitivity data for GBM may be systematically misleading about what would work in the whole tumor.

Feasibility: Medium

Viral-Cancer Molecular Mimicry Atlas

Common cold virus antibodies accidentally target hepatocellular carcinoma via molecular mimicry with ASPH — revealing that prior viral infection history may create natural cancer protection and that viral epitopes could be engineered into therapeutic cancer vaccines.

Feasibility: Medium

Oncolytic Virus Response Signature Database

RP1 oncolytic virus induces two molecularly distinct CD8+ T cell populations — progenitor-like precursors and terminal effectors — and a precursor-associated gene signature correlates with clinical response to RP1 plus PD-1 blockade in real melanoma patients, making this a candidate predictive…

Feasibility: Medium

PancreAI: Morphology-to-Molecular Subtype Classifier

Four morphological classes of pancreatic cancer (glandular, cribriform, solid, squamous) each have distinct transcriptomic programs and clinical implications — meaning what a pathologist sees under a microscope encodes actionable molecular information that could guide treatment decisions without…

Feasibility: Medium

Rare KRAS-Mutant Cancer Clinical Trial Finder

KRAS inhibitors showed dramatic efficacy in appendiceal adenocarcinoma — a rare cancer with almost no approved treatments — and six real patients with heavily pre-treated disease responded, demonstrating that KRAS-mutant rare cancers outside the mainstream (colon, lung, pancreatic) may be…

Feasibility: High

SCLC DLL3 Biomarker Expression Predictor

POU2F1 acts as the master transcriptional activator of DLL3 in SCLC — meaning DLL3 expression levels, which determine whether patients respond to DLL3-targeted therapies like tarlatamab, are now mechanistically explainable and potentially predictable from upstream transcription factor activity.

Feasibility: Medium

DMG Drug Repurposing Navigator

FDA-approved SSRIs synergize with CDK9 inhibitors to kill diffuse midline glioma cells — meaning drugs that are safe, cheap, brain-penetrant, and already FDA-approved may have immediate translational potential in a childhood brain cancer with no effective treatments.

Feasibility: High

Myelofibrosis Preclinical Model & Target Registry

This study created the first humanized ossicle model that faithfully reproduces myelofibrosis features including reticulin fibrosis and osteosclerosis, and identified SPP1 as a new therapeutic target — highlighting both a model gap and a drug target gap that a structured resource could help address.

Feasibility: Medium

BRCA-Lung Immunotherapy Eligibility Explorer

BRCA1/2 mutations in lung adenocarcinoma predict better responses to immune checkpoint blockade despite worse overall prognosis — creating a paradox that clinicians need tools to navigate when making immunotherapy decisions for NSCLC patients.

Feasibility: High

Pre-Cancer Cell Communication Network Atlas

Transformed breast cells use physical nanotube connections to transmit BMP signaling to normal neighbors, actively spreading a preneoplastic state — meaning early cancer initiation may be a contagious process, not just isolated mutations.

Feasibility: Medium

AML Resistance Pathway Mapper

When PI3K is blocked in AML cells, the cancer compensates by upregulating EZH1 — an escape route that can be closed by combining PI3K inhibitors with EZH1/2 dual inhibitors. This research makes a compelling case for systematically mapping known resistance bypass routes and their combination therapy…

Feasibility: Medium

Read more